Array gains on Phase III OS data in melanoma

Array BioPharma Inc. (NASDAQ:ARRY) gained $2.19 (16%) to $16.28 on Tuesday after reporting that binimetinib (MEK162) plus encorafenib (LGX818) significantly improved median overall survival compared to BRAF inhibitor Zelboraf vemurafenib in the Phase

Read the full 338 word article

User Sign In